Posted by Michael Wonder on 08 May 2020
FDA grants fast track designation for omecamtiv mecarbil in heart failure
8 May 2020 - Fast track designation highlights the urgent need for new heart failure treatment options.
Amgen and Cytokinetics today announced that the U.S. FDA has granted fast track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a cardiac myotrope, being developed for the potential treatment of chronic heart failure with reduced ejection fraction.
Omecamtiv mecarbil is a novel, selective cardiac myosin activator, also known as a cardiac myotrope,1 that binds to the catalytic domain of myosin.
